Vicor Technologies, a biotechnology company focused on the development of non-invasive medical devices using patented, proprietary PD2i nonlinear algorithm and software, has released the results of a pilot study to test the ability of its PD2i nonlinear algorithm to detect acute hypovolemia.
Vicor conducted the study in cooperation with the University of Mississippi Medical Center and Mississippi Blood Services on December 12, 2009 in Smithdale, MS.
Vicor is currently in the process of commercializing diagnostics that accurately risk stratify specific target populations for future pathological events including sudden cardiac death and autonomic nervous system dysfunction, and trauma victims in need of lifesaving intervention.
The goal of the pilot study was to test the ability of Vicor’s PD2i nonlinear algorithm to identify acute hypovolemia in blood donors as a preliminary step toward ascertaining whether it could be a useful noninvasive diagnostic for detecting blood loss from internal bleeding.
All 18 participants in the pilot study were tested prior to donation to determine a baseline PD2i value, and re-tested during and after collection. The average PD2i value of participants prior to donation was 2.60; the average PD2i value following donation was 1.80.
Vicor said that with a P value of 0.001, the study results are highly statistically significant; this indicates a better than 99% probability that the results were not achieved randomly.
David Fater, CEO of Vicor, said: “We’re extremely grateful to our colleagues at the University of Mississippi Medical Center and Mississippi Blood Services for their efforts in making this pilot study possible. We’re also very encouraged by the results achieved by the PD2i in this small pilot study, which suggest the prospect of incorporating the PD2i nonlinear algorithm into a noninvasive diagnostic for use in identifying patients who are bleeding internally.
“However, as this pilot study measures internal blood loss resulting from external blood donation, we anticipate further studies as part of our progress in commercializing a noninvasive diagnostic to detect acute hypovolemia.”